Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    19255327 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
Condition: Differentiated Thyroid Cancer

Indicates status has not been verified in more than two years